[go: up one dir, main page]

AU5056099A - Compounds for use in the treatment of inflammation - Google Patents

Compounds for use in the treatment of inflammation

Info

Publication number
AU5056099A
AU5056099A AU50560/99A AU5056099A AU5056099A AU 5056099 A AU5056099 A AU 5056099A AU 50560/99 A AU50560/99 A AU 50560/99A AU 5056099 A AU5056099 A AU 5056099A AU 5056099 A AU5056099 A AU 5056099A
Authority
AU
Australia
Prior art keywords
inflammation
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50560/99A
Inventor
Roderick Flower
Stephen Getting
Mauro Perretti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvey William Research Ltd
Original Assignee
Harvey William Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvey William Research Ltd filed Critical Harvey William Research Ltd
Publication of AU5056099A publication Critical patent/AU5056099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/69—Beta-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/695—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU50560/99A 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation Abandoned AU5056099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9816234 1998-07-24
GBGB9816234.0A GB9816234D0 (en) 1998-07-24 1998-07-24 Compounds for use in the treatment of inflammation
PCT/GB1999/002392 WO2000005263A2 (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Publications (1)

Publication Number Publication Date
AU5056099A true AU5056099A (en) 2000-02-14

Family

ID=10836177

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50560/99A Abandoned AU5056099A (en) 1998-07-24 1999-07-22 Compounds for use in the treatment of inflammation

Country Status (3)

Country Link
AU (1) AU5056099A (en)
GB (1) GB9816234D0 (en)
WO (1) WO2000005263A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides
EP1529535A1 (en) * 2003-11-06 2005-05-11 IPF PharmaCeuticals GmbH Isolation of a circulating human lipolytic peptide
CN103215328B (en) 2004-01-21 2016-08-03 诺和诺德医疗保健公司 The joint of transglutaminase mediated peptide
RU2010113972A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF CNP-22 SEPARATELY OR IN COMBINATION WITH PHYSALEMINE AS A THERAPEUTIC MEDICINE
JP2010539058A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト TRAP-14 as a therapeutic agent
BRPI0909947A2 (en) 2008-06-09 2017-06-27 Palatin Technologies Inc '' cyclic peptide, pharmaceutical composition, method of treating a disease, indication, condition or syndrome mediated by melanocortin receptor in humans or non-human mammals, and, condition treatment method that reacts to changes in melanocortin receptor function in humans or nonhuman mammals ''
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CA2761607C (en) 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
UY32690A (en) 2009-06-08 2011-01-31 Astrazeneca Ab SPECIFIC PEPTIDES FOR MELANOCORTIN RECEPTORS
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
BR112012011787B1 (en) 2009-11-23 2022-03-03 Palatin Technologies, Inc Cyclic peptide and pharmaceutical composition
CN110585215B (en) * 2019-09-19 2023-06-02 中山大学 New application of hemin and its complex in medicine
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146113A3 (en) * 1983-12-15 1987-08-19 Dieter Aderhold Active agent and therapeutical composition for the treatment of deincephalon failures of nervous deseases and skin diseases
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
FR2691465B1 (en) * 1992-05-25 1995-08-11 Pf Medicament COMPLEXES COMPRISING AT LEAST ONE ALPHA MSH-DERIVED PEPTIDE, PEPTIDE, MICROSPHERE, MEDICAMENT AND GALENIC COMPOSITION COMPRISING THE SAME.
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Also Published As

Publication number Publication date
WO2000005263A2 (en) 2000-02-03
GB9816234D0 (en) 1998-09-23
WO2000005263A3 (en) 2000-05-04

Similar Documents

Publication Publication Date Title
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
AU3201095A (en) Substituted thiazoles for the treatment of inflammation
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
AU3441197A (en) 3-ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes
AU2388895A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
AU4340700A (en) Methods and compositions for use in the treatment of hyperlipidemia
AU2337999A (en) Liquid treatment unit
AU1772399A (en) Well treatment
AU5056099A (en) Compounds for use in the treatment of inflammation
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU2001253749A1 (en) 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
AU2740899A (en) Treatment of liquids
AU2021601A (en) Composition for the treatment of dandruff
AU1878201A (en) Composition for the treatment of damaged tissue
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU9278598A (en) Use of azole derivatives for the treatment of inflammatory skin conditions
AU2160697A (en) Nsaids in the treatment of pruritus
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU1940800A (en) Combination therapy for the treatment of sepsis
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
AU2566201A (en) Compounds and methods for the treatment of pain
AU2420101A (en) Method and composition for the treatment of pain
AU2683500A (en) Compositions for the treatment of pain
AU3061199A (en) Skin treatment compositions and the use thereof
AU2713797A (en) Depigmentating agent in the treatment of melasma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase